Key result
The Abbott AxSYM Digoxin II assay demonstrated significantly less susceptibility to digoxin-like immunoreactive factors interference compared to four of six other methods (P<0.05).
Why the study?
Does the Abbott nonpretreatment AxSYM Digoxin II assay improve quantification of digoxin and reduce susceptibility to DLIFs compared to other standard assays in clinical samples?
Population
233 samples from renal patients, liver disease patients, cord blood, and third-trimester pregnancies
Comparison
Abbott nonpretreatment AxSYM Digoxin II assay vs Abbott pretreatment AxSYM, Baxter Stratus II…
Design
Other
Authors
Loading...
May favor Abbott AxSYM Digoxin II to minimize DLIF interference in monitoring; leaves open effects on dosing accuracy and outcomes.
Observational (n=233)
Yes
Does the Abbott nonpretreatment AxSYM Digoxin II assay improve quantification of digoxin and reduce susceptibility to DLIFs compared to other standard assays in clinical samples?
p-value: p=<0.05
The Abbott nonpretreatment AxSYM Digoxin II assay provides reliable digoxin quantification with minimal interference from digoxin-like immunoreactive factors compared to several other standard methods.
Azzazy et al. (1997) conducted an observational in Patients susceptible to digoxin-like immunoreactive factors (n=233). Abbott AxSYM Digoxin II assay vs. 6 other digoxin assays was evaluated on Susceptibility to interference from digoxin-like immunoreactive factors (DLIFs) (p=<0.05). The Abbott AxSYM Digoxin II assay demonstrated significantly less susceptibility to digoxin-like immunoreactive factors interference compared to four of six other methods (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: